Disease progression after discontinuation of corticosteroid treatment in a COVID-19 patient with ARDS

• 作者: Lam Nguyen-Ho
• 来源期刊: 亚太热带医药杂志（英文版）
• 年，卷（期）: 2022,（1）
• 所属期刊栏目: Letter to Editor
• 页码范围: 47-48
• 页数: 2页
• 语种: 英文
• DOI: 10.4103/1995-7645.335702

摘要

Excessive acute inflammatory response in coronavirus-induced disease 2019 (COVID-19) patients results in multiple organ injury, especially acute respiratory distress syndrome (ARDS), contributing to a high mortality of the disease[1,2]. More evidence showed that corticosteroid, an immunomodulatory agent, reduces both the need of invasive mechanical ventilation and lowers the mortality of severe COVID-19 patients. However, its optimal dose and therapeutic duration is still ambiguous. The RECOVERY trial revealed that using corticosteroid up to 10 days reduced the mortality of hospitalized COVID-19 patients[3] and a finding also upheld by a meta-analysis by Cano et al.[4]. To the best of our knowledge, currently, there is no study evaluating disease progression after discontinuation of corticosteroid treatment in COVID-19 patients with ARDS.